Warrants for up to 52.1M shares face an ownership cap at Taysha Gene Therapies (TSHA).
RA Capital Management, L.P. and affiliated entities reported an amended beneficial ownership of 32,785,574 shares, representing 9.99% of Taysha Gene Therapies (TSHA) as of September 30, 2026. This includes pre-funded warrants exercisable for up to 52,134,718 shares, but a beneficial ownership blocker prevents exercising warrants if it would exceed the 9.99% threshold. The report was filed via Schedule 13G/A, detailing shared voting and dispositive power among the reporting persons.
Taysha Gene Therapies Reports Narrower Than Expected Loss for Q3 2026
Taysha Gene Therapies (NASDAQ: TSHA) reported a diluted loss of $0.10 per share for Q3 2026, which was narrower than the estimated loss of $0.13 per share. Despite beating analyst expectations, the company's net loss widened year-over-year to $39.1 million, largely due to a significant increase in general and administrative expenses. Wall Street analysts maintain a bullish outlook, focusing on the company's gene therapy pipeline potential.
Taysha Gene Therapies Q3 2026 Earnings Call Transcript
Taysha Gene Therapies (NASDAQ: TSHA) reported a Q3 2026 net loss of $39.1 million, with increased R&D and G&A expenses due to clinical trials and commercial readiness. The company completed dosing in its REVEAL and ASPIRE trials for Taysha 102, with a favorable safety profile observed, and achieved a major manufacturing milestone for potential BLA submission in the first half of 2027. Taysha also plans to nominate a new gene therapy candidate for a CNS disorder in the first half of 2027 to expand its genetic medicines franchise.
Taysha Gene Therapies Q3 2026 Earnings Call Is Live
Taysha Gene Therapies (TSHA) has commenced its Q3 2026 earnings call, where executives will discuss the latest financial results. This call provides an opportunity for management to elaborate on the company's performance, potentially revealing new information that could influence market sentiment. Investors and analysts will be keen to hear discussions on future demand, margins, and capital spending.
Form 8K Taysha Gene Therapies Inc For: 12 November By Investing.com
This article announces that Taysha Gene Therapies Inc. filed a Form 8K on November 12. The filing is brief, providing only the company name and the date of the filing, with a note on the stock symbol TSHA.
Form 8K Taysha Gene Therapies Inc For: 12 November By Investing.com
This article from Investing.com announces that Taysha Gene Therapies Inc. (TSHA) filed a Form 8K on November 12. The filing is noted alongside the company's stock performance, which showed a -2.61% change. The content primarily serves as a notification of the SEC filing for financial market observers.
Taysha Reports $39.1 Million Third-Quarter Loss as TSHA-102 Trials Continue
Taysha Gene Therapies reported a net loss of $39.1 million for the third quarter ended September 30, 2026, with no revenue. The company's TSHA-102 trials for Rett syndrome are ongoing, and it expects topline data and FDA feedback in the first half of 2027. Taysha anticipates its current cash resources will fund operations into the second half of 2028.
Taysha Beats On A Narrower-Than-Expected Loss As PPQ Completion De-Risks TSHA-102, But The Investment Case Now Rests On One Binary 1H 2027 Event
Taysha Gene Therapies reported a narrower-than-expected third-quarter loss of $0.10 per share, driven by a drop in R&D spending after completing its process performance qualification (PPQ) manufacturing campaign for TSHA-102. While the company de-risked operational aspects and strengthened its balance sheet, the investment case now hinges entirely on the pivotal data and FDA feedback for TSHA-102 in the first half of 2027, with the potential for submission delays if the FDA requires 12-month data.
Taysha Gene Therapies (TSHA): Q3 2026 net loss $39.1M ($0.10/sh) vs...
Taysha Gene Therapies (TSHA) reported a Q3 2026 net loss of $39.1 million ($0.10/share), compared to $32.7 million a year ago. The company stated it has a cash runway of $422.8 million extending into 2028 and has completed the PPQ for TSHA-102, with FDA feedback expected in the first half of 2027. The announcement also included historical stock performance following previous headlines.
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies announced its third-quarter 2026 financial results, highlighting significant progress in its TSHA-102 program for Rett syndrome. The company successfully completed a BLA-enabling manufacturing campaign and expects to report topline data from its REVEAL pivotal trial and receive FDA feedback on its BLA submission pathway in the first half of 2027. Taysha reported a net loss of $39.1 million for the quarter but maintains strong cash reserves projected to last into the second half of 2028.
Taysha Gene Therapies earnings up next as analysts eye Rett trial
Taysha Gene Therapies is set to release its third-quarter results, with analysts and investors focused on updates regarding its lead gene therapy program for Rett syndrome, TSHA-102. Despite expected minimal near-term revenue and ongoing cash burn, Wall Street maintains a "Strong Buy" consensus with significant upside potential due to confidence in the clinical-stage biotech's pipeline for rare neurological diseases. Key areas of interest include TSHA-102's clinical progress, cash management, and broader pipeline developments.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies announced an inducement grant under Nasdaq Listing Rule 5635(c)(4), awarding restricted stock units representing 25,000 shares of common stock to two new employees. These RSUs were granted on November 2, 2026, under the company's 2023 Inducement Plan to incentivize their employment. The shares will vest in four equal annual installments, contingent on continued service.
Taysha is developing a gene therapy for Rett syndrome. Its quarterly results are due Nov. 12.
Taysha Gene Therapies (TSHA) announced it will release its third-quarter 2026 financial results and host a conference call and webcast on November 12, 2026, at 8:30 AM Eastern Time. The clinical-stage biotechnology company is focused on developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, with its lead program, TSHA-102, targeting Rett syndrome.
Taysha Gene Therapies to Release Third Quarter 2026
Taysha Gene Therapies, Inc. announced that it will report its financial results for the third quarter ended September 30, 2026, and host a conference call and webcast on Thursday, November 12, 2026, at 8:30 AM Eastern Time. The company is a clinical-stage biotechnology firm focused on developing gene therapies for severe monogenic diseases of the central nervous system, including its lead program TSHA-102 for Rett syndrome. An archived replay of the webcast will be available on the company's website.
Taysha Gene Therapies, Inc. (TSHA) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Taysha Gene Therapies, Inc. (TSHA), showing the average monthly price return from 2020 to 2026. As of November 4, 2026, TSHA closed at $4.36, up 6.60%. The article is primarily a display page for financial data and historical seasonality of the stock.
Taysha Gene Therapies, Inc. Estimates – NASDAQ:TSHA
This article provides access to financial actuals and analyst estimates for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) on TradingView. Users can explore reported data and estimates across income statements, balance sheets, cash flow statements, and valuation metrics, as well as compare actual results with average, high, and low estimates. The platform also allows for visualizing financial trends over time.
Neurogene, Taysha near finish line in ‘two-horse race’ for first Rett syndrome gene therapy
Taysha Gene Therapies and Neurogene are in a "two-horse race" to bring the first gene therapy for Rett syndrome to market, with both companies anticipating pivotal trial readouts in 2027. Their gene therapies, TSHA-102 and NGN-401, respectively, have shown promising long-term efficacy with 100% response rates in early-stage trials, offering new hope for patients with this rare neurodevelopmental disorder. While experts are optimistic about the potential for significant improvements, they caution against using the word "cure" due to the complexity of CNS diseases.
Taysha Gene Therapies stock hits 52-week low at 3.69 USD
Taysha Gene Therapies Inc. (TSHA) stock has fallen to a 52-week low of $3.69, reflecting a 27.55% decrease over the past year and a 51% drop from its 52-week high. The company also reported a wider-than-expected loss of $0.13 per share for Q2 2026, slightly missing analyst forecasts. Despite these challenges, Taysha Gene Therapies continues to advance its lead Rett syndrome gene therapy, TSHA-102.
Taysha Gene Therapies stock hits 52-week low at 3.69 USD
Taysha Gene Therapies Inc. (TSHA) stock has fallen to a 52-week low of $3.69, representing a 27.55% decrease over the past year and a 51% drop from its 52-week high. This downturn follows a wider-than-expected loss in Q2 2026, though the company continues to advance its lead Rett syndrome gene therapy, TSHA-102. InvestingPro analysis suggests the stock is in oversold territory but trading near its fair value.
Four new hires get Taysha stock awards tied to 384,000 shares, plus rights to buy more.
Taysha Gene Therapies granted equity awards to four new employees on October 1, 2026, as an inducement for employment, as per Nasdaq Listing Rule 5635(c)(4). These awards include restricted stock units (RSUs) representing 384,000 common shares and an option to purchase 92,400 common shares. The RSUs vest in four equal annual installments, while the stock option vests 25% on the first anniversary and the remaining 75% monthly over 36 months, both contingent on continued service.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced an inducement grant to four new employees, consisting of 384,000 restricted stock units and options to purchase 92,400 shares of common stock. These grants were made under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with vesting schedules tied to continued employment. This move aims to attract and retain talent for the clinical-stage biotechnology company focused on gene therapies for CNS diseases.
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
Taysha Gene Therapies announced multiple encore presentations at the 55th Child Neurology Society Annual Meeting, highlighting data from its TSHA-102 program for Rett syndrome. These presentations will include results from the REVEAL Part A Phase 1/2 trial, discussions on Rett syndrome developmental assessments, and insights from natural history studies. The company is advancing TSHA-102 as a potential one-time gene therapy to address the genetic root cause of Rett syndrome.
Taysha Gene Therapies Announces Multiple Encore
Taysha Gene Therapies announced multiple encore presentations for its TSHA-102 program in clinical evaluation for Rett syndrome at the 55th Child Neurology Society Annual Meeting. These presentations will highlight data previously shared at the 2026 International Rett Syndrome Foundation (IRSF) Scientific Meeting, including an oral presentation on functional gains and poster presentations on developmental plateaus and assessment tools. The company will also host a symposium on Rett syndrome across the disease continuum.
Taysha Gene Therapies, Inc. (TSHA) Stock Price, News, Quote & History
This page provides a comprehensive overview of Taysha Gene Therapies, Inc. (TSHA), including its current stock price, historical data, key statistics, and financial performance. It also details the company's focus on developing gene therapies for severe monogenic central nervous system diseases and lists their primary drug candidates. The article includes analyst insights and a comparison of TSHA's returns against the S&P 500.
Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating
Wolfe Research has initiated coverage on Taysha Gene Therapies (TSHA.US) with a Buy rating. This indicates a positive outlook from the research firm regarding the company's stock performance.
Taysha Gene Therapies, Inc. launches webinar to advance patient-centered Rett syndrome trials
Taysha Gene Therapies, Inc. is promoting a webinar focused on advancing patient-centered clinical trials for Rett syndrome. The webinar, hosted by the Child Neurology Society and featuring Dr. Arthur Partikian, will discuss how natural history research can refine treatment expectations and prepare the community for new therapies. This initiative aligns with Taysha's broader efforts in engaging clinical and patient communities in rare diseases, following recent advancements like a commercial supply agreement with Catalent for TSHA-102 and a 6.7% stock increase after an earnings announcement.
New Taysha Gene Therapies hires receive 349,000-share stock grant
Taysha Gene Therapies (Nasdaq: TSHA) announced it granted 349,000 restricted stock units (RSUs) to three new employees on February 2, 2026, as an inducement award under its 2023 Inducement Plan. These RSUs will vest in four equal annual installments, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's strategy to attract and retain talent in the gene therapy sector.
TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA)
Taysha Gene Therapies (TSHA) recently reported Q2 2026 results with a net loss of US$46.64 million, but achieved a 100% responder rate in its pivotal TSHA-102 Rett syndrome trials. The company also expanded its manufacturing partnership with Catalent and secured US$230 million in financing, extending its cash runway to late 2028. These developments are expected to significantly reshape the investment outlook for Taysha, as it prepares for potential regulatory filing and commercialization of TSHA-102.
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
Taysha Gene Therapies announced the completion of patient dosing in both the REVEAL pivotal and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with positive longer-term follow-up data showing consistent functional gains. The company has expanded its manufacturing partnership with Catalent and strengthened its financial position with a $230 million financing, extending its cash runway into the second half of 2028. Taysha anticipates reporting top-line data from the REVEAL trial's 6-month interim analysis and receiving FDA feedback on the BLA pathway in the first half of 2027.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus "Buy" recommendation from fourteen brokerages, with an average 12-month price target of $12.7692. Several analysts have recently increased their price targets for the stock. Despite missing its last quarterly EPS estimate, the company holds a market capitalization of $2.02 billion and analysts anticipate a -0.51 EPS for the current year.
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies (TSHA) completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, a gene therapy candidate for Rett syndrome, and is preparing for a potential biologics license application (BLA) submission. The company plans a six-month interim analysis of the REVEAL trial, which could accelerate its BLA filing. Despite a reported Grade 2 peripheral sensory neuropathy in one patient, the therapy has been generally well-tolerated, and manufacturing preparations for commercialization are underway.
RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA)
RA Capital Management and affiliated funds have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.99% in Taysha Gene Therapies (TSHA) common stock as of June 30, 2026. This ownership includes common shares and a portion of pre-funded warrants, capped by a "Beneficial Ownership Blocker" at 9.99%. The filing indicates RA Capital maintains voting and dispositive power over these securities.
Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have reported a beneficial ownership of 16,244,339 shares, or 5.1%, of Taysha Gene Therapies, Inc. common stock as of June 30, 2026. This disclosure was made in an Amendment No. 2 to Schedule 13G filing. The filing details shared voting power over 16,067,509 shares and shared dispositive power over all 16,244,339 shares, with Morgan Stanley Capital Services LLC specifically reporting 5.0% ownership.
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies announced its second-quarter 2026 financial results, highlighting the completion of dosing in its REVEAL pivotal and ASPIRE trials for TSHA-102 in Rett syndrome. The company expects to report topline data from a 6-month interim analysis and receive FDA feedback on its Biologics License Application (BLA) submission pathway in the first half of 2027. Taysha also completed a $230 million follow-on offering, extending its cash runway into the second half of 2028, and expanded its manufacturing partnership with Catalent.
Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return
Taysha Gene Therapies (TSHA) has seen a significant 232% return over three years, yet its current valuation, particularly its Price-to-Book ratio of 9.8x against an industry average of 2.5x, suggests it trades at a premium. The company's valuation appears to already price in expectations for its TSHA-102 gene therapy for Rett syndrome, implying a high perceived risk and reliance on successful clinical and regulatory outcomes to sustain its current premium. Investors should assess whether the future path for TSHA-102 justifies this high valuation or if any setbacks could lead to a multiple reset.
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary
Taysha Gene Therapies, Inc. (TSHA) released its Q2 2026 earnings call summary, highlighting the completion of dosing in key trials and anticipating top-line data in H1 2027. The company's strategic focus on developmental milestones and a strong safety profile are intended to support BLA submission and market access, with current cash reserves projected to last into H2 2028.
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies announced the completion of dosing for its REVEAL pivotal trial and ASPIRE trial for TSHA-102, a gene therapy candidate for Rett syndrome, with plans for a potential biologics license application submission. The company reported positive longer-term data from Part A of the REVEAL trial, showing significant developmental milestone gains and functional improvements across various domains. Despite a reported Grade 2 peripheral sensory neuropathy event in one patient, Taysha emphasized that TSHA-102 has been generally well tolerated and is advancing manufacturing and commercial preparations, anticipating cash resources to fund operations into the second half of 2028.
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside
Taysha Gene Therapies, Inc.'s stock has seen its average 12-month price target increased to $13.33, up from $13.25, according to 12 analysts. This new target implies a potential 100% upside based on the Aug. 11 closing price. The consensus rating for the stock remains a "Buy" with all 12 analysts recommending it.
Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA
Renaissance Technologies LLC significantly increased its stake in Taysha Gene Therapies (NASDAQ: TSHA) by 141.5% in the first quarter, acquiring an additional 242,103 shares. This brings their total holding to 413,203 shares valued at approximately $1.85 million. Despite this institutional confidence and a consensus "Buy" rating from analysts, Taysha Gene Therapies missed its quarterly EPS expectations.
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies announced the completion of dosing in its REVEAL pivotal trial and ASPIRE study for TSHA-102, a gene therapy for Rett syndrome, with an interim analysis potentially accelerating a BLA filing to early 2027. Long-term data from Part A showed all 12 patients achieved developmental milestones at 12 months, significantly exceeding the FDA's 33% efficacy threshold. Despite a wider Q2 net loss of $46.6 million due to increased development costs, the company's $455.4 million cash position is projected to fund operations into the second half of 2028.
Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast
Taysha Gene Therapies (TSHA) reported a wider second-quarter loss for 2026, missing Wall Street's EPS forecast by $0.01, with shares falling 6.44% in after-hours trading. Despite the earnings miss, the company highlighted significant clinical progress with its lead Rett syndrome gene therapy, TSHA-102, completing dosing in two pivotal trials and maintaining a cash runway into the second half of 2028. Management focused on ongoing clinical development, manufacturing readiness, and commercialization plans, addressing questions on a mild treatment-related adverse event and the innovative endpoint strategy for regulatory approval.
Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million
Taysha Gene Therapies reported a widening net loss of $46.6 million in Q2 2026, missing EPS estimates, primarily due to increased R&D spending on its lead candidate TSHA-102 for Rett syndrome. Despite the losses, the company strengthened its cash reserves to $455.4 million through equity financing, expected to fund operations into the second half of 2028. Taysha also completed dosing in its pivotal REVEAL and ASPIRE trials, with top-line results anticipated in the first half of 2027, and secured a commercial manufacturing partnership with Catalent.
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss
Taysha Gene Therapies (TSHA) reported a Q2 loss of $0.13 per share, which is wider than the FactSet estimate of a $0.11 loss. This financial update indicates that the company's performance for the second quarter of 2026 fell short of analyst expectations. The article also provides a company profile, outlining its focus on gene therapies for central nervous system diseases.
Taysha Gene Therapies Q2 net loss widens on higher R&D costs
Taysha Gene Therapies reported a widening net loss in the second quarter due to increased research and development costs. The article, sourced from Reuters and provided via TradingView, indicates that the full details are available to subscribers.
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
Taysha Gene Therapies (NASDAQ:TSHA) reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Despite this, the stock rose 5.3% to $6.71, supported by strong liquidity and significant institutional ownership. Analyst sentiment is generally positive, with an average "Buy" rating and a $12.77 price target.
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies announced its second-quarter 2026 financial results, highlighting the completion of dosing in its pivotal REVEAL and ASPIRE trials for TSHA-102 in Rett syndrome. The company expects to report topline data and FDA feedback on the BLA submission pathway in the first half of 2027, bolstered by positive longer-term data and a strengthened cash runway into 2H 2028 from a recent $230 million offering. TSHA-102 continues to show a generally well-tolerated safety profile and broad functional gains.
Taysha Gene Therapies (TSHA) Is Up 10.2% After Securing Long-Term TSHA-102 Manufacturing Capacity
Taysha Gene Therapies (TSHA) saw a 10.2% stock increase after announcing a commercial supply agreement with Catalent for the manufacturing of TSHA-102, its investigational Rett syndrome gene therapy. This deal secures long-term GMP capacity, preparing Taysha for potential commercialization, though the company remains loss-making and relies on upcoming clinical data and regulatory decisions for value inflection. Analysts project significant revenue growth and a shift to profitability by 2029 for Taysha.
Taysha Gene faces earnings test as Rett therapy advances
Taysha Gene Therapies Inc. (TSHA) is set to report its second-quarter earnings, with investor focus primarily on the progress of its lead gene therapy candidate, TSHA-102, for Rett syndrome, rather than its financial results. Analysts expect a loss of $0.12 per share on $300,000 in revenue, and while the company is pre-commercial and unprofitable, Wall Street maintains a "strong buy" rating with a significant upside potential. Key areas for investors include updates on TSHA-102's clinical development, patient enrollment, trial timelines, safety data, and the company's cash burn and runway.
Taysha Gene faces earnings test as Rett therapy advances
Taysha Gene Therapies Inc. is reporting second-quarter earnings, with focus primarily on the progress of its lead gene therapy candidate, TSHA-102, for Rett syndrome, rather than its financial results. Analysts expect continued losses but maintain a "strong buy" rating, anticipating significant upside. Investors will be keen on updates regarding clinical trial timelines, patient enrollment, safety data, and the company's cash burn and commercial strategy for TSHA-102.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies announced an inducement grant to a new employee on August 3, 2026, comprising restricted stock units for 144,000 shares and an option to purchase 92,400 shares. This grant was made under the company's 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The RSUs and stock options have multi-year vesting schedules, subject to continued employment, with the stock option's exercise price set at the closing price on the grant date.